|Bid||123.32 x 300|
|Ask||123.42 x 100|
|Day's Range||120.45 - 123.38|
|52 Week Range||77.58 - 153.15|
|PE Ratio (TTM)||-218.83|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte's consolidated revenues rose ~32.5% to ~$326.4 million in 2Q17, compared with ~$246.3 million in 2Q16.
Incyte reported revenues of ~$326.4 million for 2Q17, compared with ~$246.3 million for 2Q16.
Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates.